Swedish Orphan Biovitrum appoints president and ceo

Geoffrey McDonough takes the role, joining the firm from Genzyme

Geoffrey McDonough, currently Genzyme’s president of Europe, Middle East and Africa (EMEA), will move Swedish Orphan Biovitrum (Sobi) as president and ceo on 15 August. He will succeed Kennet Rooth, who has been acting ceo since the beginning of the year.

McDonough has held several leading positions within Genzyme in the US since 2002, beginning his career with the firm in corporate development.

‘Geoff is well-recognised for his solid and broad commercial and clinical expertise and for his background in the orphan drug and niche speciality market,’ said Bo Jesper Hansen, chairman of Sobi.

‘He will lead Sobi toward our vision of becoming the leading niche speciality pharmaceutical company in Europe.’

You may also like

Research & Development

Sobi Orfadin capsules approved in Saudi Arabia

Swedish Orphan Biovitrum's orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1
Manufacturing

Sobi signs manufacturing agreements with Pfizer

Sobi is dedicated to developing and delivering innovative therapies for rare diseases
Pharmaceutical

Ardena strengthens executive team to drive its next phase of growth

Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally
Pharmaceutical

Backed by investments exceeding $1 billion, PCI Pharma Services announces major expansion of US sterile fill-finish and drug-device delivery combination capabilities

As pharma manufacturers prioritise US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging
Manufacturing

New Romaco Maximus 400 tablet coater at interpack

Ideal for pharmaceutical coatings with a very large weight gain
Pharmaceutical

SGS launches GMP-compliant NMR testing for Chinese pharma industry

The inspection and certification specialist will now offer nuclear magnetic resonance (NMR) testing for analysis of both drug substances and drug products across China
Media

Romaco to debut Maximus 400 tablet coater with automatic baffle adjustment at Interpack

The Maximus 400 tablet coater is the first to automatically adjust baffle geometry as tablet bed volume increases, with an optional energy recovery system cutting consumption by up to 50%, alongside the VENTILUS Lab fluid bed processor, capable of reducing batch processing times by 25%
Subscribe now